Építés alatt – nem éles oldal
Belépés
Visszavonva2. fázis

A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Refractory Angina

A legfontosabb adatok

Ki végzi
Imbria Pharmaceuticals, Inc.
Hol
Boston (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Visszavonva
Fázis
2. fázis
Kezdés
2020. máj. 1.
Befejezés
2025. ápr.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • IMB-1018972
  • Placebo oral tablet
A regiszteradat frissítve
2025. november 10.
Miért állt le
Coronavirus pandemic

Ki vehet részt

Életkor
18 év – 85 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 25 feltétel megnézéseKevesebb

Ki vehet részt

  • Is between the ages of 18 and 85 years, inclusive
  • Is capable of understanding the written informed consent, and providing signed, dated, and witnessed written informed consent
  • Has complied with and is willing to continue to comply with the specified procedures (eg, angina diary during screening) and complete specific follow-up evaluations
  • Has coronary artery disease confirmed by at least one of the following:; Documented prior MI, CABG surgery, or PCI -OR-; Angiography performed within the 24 months prior to Visit 1 confirming CAD (eg, evidence of ≥70% stenosis of at least one major coronary artery or diffuse CAD)
  • Has evidence of stress induced ischemia documented by either:; Protocol-specified ETT ECG demonstrating at least 0.5 mm exercise-induced ST segment depression with onset <9 minutes on at least 1 of the screening ETTs -OR-; Prior evidence of stress-induced reversible perfusion defect in the last 24 months (without intervening revascularization) identified by at least one of the following:; Radionuclide imaging study; Echocardiographic imaging study; FFR <0.8; IFR <0.89; FFR CT <0.8; CFR <2.5
  • Has a minimum 3 month history of exertional angina, including angina with a minimum frequency of 2 anginal episodes per week on average for the 2 weeks prior to enrolling in the study while on optimal guideline directed medical therapy for their angina
  • Is on optimal, dual agent, antianginal therapy for their angina for at least 1 month prior to the first screening ETT. Consistent with ACC/AHA and ESC Class I guideline directed medical therapy (GDMT), criteria for optimal therapy include treatment with both: (a) a beta-adrenergic blocking agent and treatment with (b) a calcium channel blocker OR a long-acting nitrate. If unacceptable side effects are intolerable and documented with a therapy listed in (a) or (b), treatment with only 1 antianginal medication is acceptable. Additionally, patients should be treated with short-acting nitrates per GDMT
  • Is currently not clinically indicated for coronary revascularization (ie, PCI or CABG) in the opinion of the principle investigator at the time of screening through 6 months after randomization
  • Has a CCS score of II, III or stabilized IV for 1 month prior to screening
  • Meets the following requirements after 2 screening modified Bruce protocol ETTs:; Stopping the treadmill test due to angina on each test b. Total exercise duration must fall between 3 and 9 minutes on each test c. To document inducible myocardial ischemia: i. For those patients with interpretable ECGs, at least 0.5 mm exercise induced ST segment depression must occur with onset <9 minutes on at least 1 of the screening ETTs; Difference in TED between the 2 qualifying ETTs must not exceed 20% of the longer test or 1 minute, whichever limit is smaller; Consideration of a third ETT may be discussed by the investigator with the study medical monitor, who may authorize the performance of a third ETT a minimum of 5 days and no more than 10 days after the second ETT

Ki nem vehet részt

  • If any of the following have occurred:; Use of TMZ anytime in prior history; In the prior 6 months:; Diagnosis of NYHA Class 3 or 4 (heart failure); Hospitalization for heart failure; Coronary artery bypass graft surgery; Cardiac resynchronization therapy placement or adjustments to CRT parameters; Implantable cardioverter defibrillator or biventricular pacemaker placement; In the prior 3 months:; Hospitalization for a cardiovascular indication; Cerebral vascular accident; Transient ischemic attack; Percutaneous coronary intervention; In the prior 1 month:; Use of perhexiline or meldonium
  • Has a positive test for drugs (eg, opiates, methadone, cocaine, amphetamines [including ecstasy], or barbiturates) at screening
  • Has a history of moderate to severe valvular heart disease defined as aortic stenosis (valve area <1.5 cm2), aortic insufficiency, mitral stenosis (valve area <1.5 cm2), or mitral valve regurgitation of grade 3 or worse
  • Has a history of Parkinson disease, Parkinsonian symptoms, tremors, restless leg syndrome, or other related movement disorders
  • Has a history of vasospastic angina or microvascular angina
  • Has a history of alcohol abuse or drug addiction
  • Has a positive test for HBsAg, HCV antibodies, or HIV1/2 antibodies at screening
  • Has significant hepatic disease, with increased liver function tests such as total bilirubin, aspartate aminotransferase, or alanine aminotransferase more than 2 times of ULN at baseline (excluding patients with documented history of Gilbert syndrome)
  • Has severe renal impairment (ie, creatinine clearance <30 mL/min at screening, measured using 4-variable modification of diet in renal disease equation)
  • Has an exacerbating cause for angina (eg, anemia [ie, hemoglobin <10 g/dL], uncontrolled hypertension [ie, BP ≥160/90 mmHg], hyperthyroid, or rapid AF [ie, AF with average rate >120 beats per minute]) at screening
  • Has long-QT and life-threatening LV arrhythmia
  • Has comorbidities limiting life expectancy to less than 3 years
  • Is pregnant, planning pregnancy, or lactating
  • Is participating in another research study
  • Is an employee or family member of the investigator or study site personnel

Helyszínek itt: Egyesült Államok

  • Boston, MassachusettsHospital not named in the registry

A vizsgálatról

Mit akar kideríteni a vizsgálat

The objectives of the study are to assess the safety, tolerability, and potential efficacy of IMB-1018972 on patients with refractory angina. Study will assess functional capacity employing a modified Bruce Protocol treadmill ETT, patient reports of angina symptoms via an electronic diary, and activity using an accelerometer.

A vizsgálat 2 csoportja

  • IMB-1018972A vizsgált kezelés

    Participants will receive IMB-1018972 (200 mg) MR tablets twice daily for 16 weeks

  • PlaceboPlacebo, összehasonlításként

    Participants will receive matching placebo tablets twice daily for 16 weeks

    Kezelés: Placebo oral tablet

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Refractory Angina
A regiszteradat frissítve
2025. november 10.